Follow us on Twitter
twitter icon@FreshPatents


Therapeutical patents

      

This page is updated frequently with new Therapeutical-related patent applications.




 Direct immunohistochemistry assay patent thumbnailDirect immunohistochemistry assay
The application is to antibodies which have been labelled with polyenzymes (multiple enzymes), specifically polyperoxidases, for use in direct immunohistochemical assays of tissues. The antibodies used diagnostically may also be antibodies which are used therapeutically..
Novodiax, Inc.


 Methods and kits for treating and classifying individuals patent thumbnailMethods and kits for treating and classifying individuals
The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological and/or mitochondrial dysfunction or disorder. In general, the individuals are treated and/or classified based on the presence of a loss-of-function mutation in nuclear dna encoding one or more proteins selected from the group consisting of aldh1l1, aldh1l2, folr1, fpgs, gcsh, gldc, mthfd1, mthfd1l, mthfd2, mthfd2l, mthfs, mtrr, shmt1, shmt2 and slc25a32.
Courtagen Life Sciences, Inc.


 Organic compositions to treat hsf1-related diseases patent thumbnailOrganic compositions to treat hsf1-related diseases
The present disclosure relates to methods of treating heat shock factor 1 (hsf1)-related diseases such as cancer and viral diseases, using a therapeutically effective amount of a rnai agent to hsf.. .
Arrowhead Pharmaceuticals, Inc.


 Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function patent thumbnailMonoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory t cell function
Methods for regulating t cell function in a subject, particularly regulatory t cell activity are provided. Methods of the invention include administering to a subject a therapeutically effective amount of an interleukin 35-specific binding agent, such as an antibody or small molecule inhibitor.
St. Jude Children's Research Hospital


 Pyridine derivatives patent thumbnailPyridine derivatives
The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds.
Asana Biosciences, Llc


 Crystalline coating and release of bioactive agents patent thumbnailCrystalline coating and release of bioactive agents
Articles-of-manufacturing comprising an object having a surface and at least a first layer of a first therapeutically active agent being deposited onto at least a continuous portion of the surface, wherein at least 50 weight percents of the first layer is the first therapeutically active agent in a crystalline form are disclosed. Methods utilizing such articles-of-manufacturing for treating medical conditions are also disclosed.
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.


 Composition and  delivery of hydrophobic active agents patent thumbnailComposition and delivery of hydrophobic active agents
Disclosed herein is a delivery composition for administering a hydrophobic active agent. In one embodiment, a delivery composition for local administration of a hydrophobic active agent to a tissue or organ of a patient is disclosed.
Surmodics, Inc.


 Selective local inhibition of tnfr1-mediated functions at the site of antigen/allergen presentation patent thumbnailSelective local inhibition of tnfr1-mediated functions at the site of antigen/allergen presentation
The invention relates to a pharmaceutical composition for the modulation of t cell and b cell responses made of one or more preparations and comprising a therapeutically effective dose of at least one inhibitor of tnfr1-mediated functions and of at least one antigen or allergen.. .
Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt Gmbh


 Multivalent vlp conjugates patent thumbnailMultivalent vlp conjugates
The invention is directed to vaccines comprising capsular polysaccharides conjugated to one or more components of virus like particles (vlp), and methods for the administration of and methods for the manufacture of vaccines of the invention. Preferably vaccines of the invention generate a therapeutically effective response in an individual in need thereof to multiple strains and/or serotypes of the same or of different infectious agents.
Inventprise, Llc


 Compositions of hyaluronan with high elasticity and uses thereof patent thumbnailCompositions of hyaluronan with high elasticity and uses thereof
The present invention provides compositions comprising hyaluronan with high elasticity, as well as methods for improving joint function, reducing pain associated with joint function and treating osteoarthritis by introducing into a joint a therapeutically effective amount of a composition comprising hyaluronan with high elasticity.. .
Matrix Biology Institute


Pharmaceutical composition based on a hepatoprotector and prebiotic, and administrating

The invention relates to medicine, hepatology and pharmacology and can be used for producing and using a pharmaceutical composition based on a hepatoprotector and a prebiotic for treating and preventing liver diseases which are caused by lipid-cholesterol exchange and selected from the following group: cholelitiasis mainly with cholesterol stones, alcoholic and non-alcoholic steatohepatitis, biliary cirrhosis, cholesterol imbibition gallbladder and drug-induced and toxic liver damage. The pharmaceutical composition is administered by mouth and contains a hepatoprotector and a prebiotic taken, as an active agent, in therapeutically effective doses.

Pharmaceutical composition

This invention relates to pharmaceutical compositions for oral administration to treat, for example, acute radiation sickness, wherein the composition comprises, for example, a first agent which is selected from the group consisting of beta-carotene, and pharmaceutically acceptable derivatives thereof; a therapeutically effective amount of a second agent which is selected from the group consisting of cholic acid, derivatives thereof, and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient.. .

Antimetabolite agent combinations in the treatment of cancer

A method treating cancer in a subject comprises administering to the subject a therapeutically effective amount of an antimetabolite agent that induces formation of ap sites in cancer cells of the subjects and an amount ap endonuclease inhibitor effective to potentiate the cytotoxicity of the antimetabolite agent to the cancer cells.. .
Case Western Reserve University

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
Texas Southern University

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
The Board Of Regents Of The University Of Texas System

Methionine aminopeptidase inhibitors for treating infectious diseases

The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivative thereof or a pharmaceutical salt thereof..
The Board Of Regents Of The University Of Texas System

Methods of using sustained release aminopyridine compositions

A pharmaceutical composition which comprises a therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at about 12 hours and the use of the composition to treat various neurological diseases, including multiple sclerosis. A method of selecting individuals based on responsiveness to a treatment, including, for example, identifying individuals who responded to treatment with a sustained release fampridine composition..
Acorda Therapeutics, Inc.

Surfactant-free hiv protease inhibitor composition and manufacturing thereof

Disclosed are pharmaceutical compositions, e.g., in the form of tablets, containing a therapeutically effective amount of an hiv protease inhibitor, e.g., ritonavir, a pharmaceutically acceptable aqueous-soluble polymer, and an erosion-enhancing agent having a particle size distribution in the range of about 1 μm to about 350 μm, wherein the composition is substantially free or free of surfactant. Methods of making the compositions, and methods of using them to treat hiv infection are also provided..
Kashiv Pharma, Llc

Compounds for treating ophthalmic diseases and disorders

The present invention relates generally to the field of ocular therapeutics and the development thereof for use in humans or animals. More particularly, it relates to dhodh inhibitor compounds and their use for the treatment of ophthalmic diseases and disorders.
Panoptes Pharma Ges.m.b.h.

Bh4 antagonists and methods related thereto

The disclosure relates to bh4 inhibitors and therapeutic uses relates thereto. In certain embodiments, the disclosure relates to methods of treating or preventing cancer, such as lung cancer, comprising administering therapeutically effective amount of a pharmaceutical composition comprising a compound disclosed herein or pharmaceutically acceptable salt to a subject in need thereof..
The Board Of Regent Of The University Of Texas System

Gaba analog prodrug sustained release oral dosage forms

Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective..
Xenoport, Inc.

Matrix-metalloproteinase (mmp) inhibitory extract and methods of use thereof

A cosmetic skin care product comprising a therapeutically effective amount of a honey extract is described, the honey extract having a phenolic compound to saccharides ratio of at least 5 times greater than the raw honey from which the extract is derived and including a mixture of at least ethanol, water and one or more mmp inhibitory phenolic compounds.. .
Comvita Limited

Pro-pigmenting peptides

The invention is directed to the use of at least one peptide of formula: x-(xaa1)n-pro*-(xaa2)m-y (i) with: —n=0, 1 or 2; -m=0 or 1 and if m=0 then n≠0-xaa1 is: -an hydrophobic aminoacid selected from alanine (ala, a), valine (val, v), methionine (met, m), leucine (leu, l), isoleucine (ile, i), phenylalanine (phe, f), proline (pro, p) and analogues and derivatives thereof; —a polar aminoacid selected from serine (ser, s), threonine (thr, t), tyrosine (tyr, y), asparagine (asn, n), glutamine (gln, q) and analogues and derivatives thereof; —or glycine (gly, g); when n=2 the two aminoacids xaa1 can be the same or different; -xaa2 is: —an hydrophobic aminoacid selected from alanine (ala, a), valine (val, v), methionine (met, m), leucine (leu, l), isoleucine (ile, i), phenylalanine (phe, f), proline (pro, p) and analogues and derivatives thereof; —a basic aminoacid selected from arginine (arg, r), lysine (lys, k) and histidine (his, h) and analogues and derivatives thereof; —glycine (gly, g) or serine (ser, s); —at the n terminal end of the peptide, x is selected from h, —co—r1 and —so2—r1; —at the c terminal end of the peptide, y is selected from oh, or1, nh2, nhr1 or nr1r2, r1 and r2 being independantly from each other, selected from an alkyle, aryle, aralkyle, alkylaryl, alkoxy and aryloxy group, that can be linear, branched, cyclic, poly-cyclic, non-saturated, hydroxylated, carbonylated, phosphorylated and/or sulphured, with the possibility to have in said group skeleton a o, s and/or n heteroatom; -pro* corresponding to a proline, an analogue or derivative thereof; excluding the peptides where x═h and y═oh, for a non therapeutical cosmetic pro-pigmenting treatment of skin. The invention also encompasses new tripeptides of formula (i) suitable for a non therapeutical cosmetic treatment of skin..
Sederma

Methods and systems for indicating a clamping prediction

End effectors with closing mechanisms, and related tools and methods may be particularly beneficial when used for minimally invasive surgery. An example surgical tool comprises a first and second jaw movable between a closed grasped or clamped configuration and an open configuration.
Intuitive Surgical Operations, Inc.

Liquid triblock copolymer

Wherein a is a hydrophilic polymer, b a hydrophobic polymer and r are end-groups, wherein r is h or a c1-c30 organic moiety and wherein the copolymer is fluid in a temperature range of 0° c. To 37° c.

Analogs of fexaramine and methods of making and using

Embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating fxr receptors in the intestines, and treating or preventing a metabolic disorder in the subject.

Live attenuated edwardsiella ictaluri vaccine and using the same

A live attenuated edwardsiella ictaluri bacterium lacking a viable gene encoding a functional evpb protein and a method of using the same to protect fish against infection from virulent edwardsiella ictaluri. The methods and compositions for protecting fish against infection from virulent edwardsiella ictaluri comprising administering to a fish a therapeutically effective amount of an attenuated edwardsiella ictaluri bacterium lacking a viable gene encoding a functional evpb protein.
Mississippi State University

Use of cgrp antagonist compounds for treatment of psoriasis

A method for treating, remedying, or preventing psoriasis by administering a therapeutically effective dose of at least one cgrp antagonist compound in a pharmaceutically acceptable formulation. The method for treating, remedying, or preventing psoriasis by administering topically and to the pre-psoriatic rim a therapeutically effective dose of at least one cgrp antagonist compound in a pharmaceutically acceptable formulation..

Compositions and methods of treating of bacterial infections with beta-lactamase inhibitors

A method of treating a bacterial infection in a subject in need thereof includes administering to the subject therapeutically effective amounts of at least one β-lactam antibiotic and at least one triazolylmethyl boronic acid.. .
Case Western Reserve University

Pharmaceutical formulation containing gelling agent

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.. .
Purdue Pharmaceuticals L.p.

Pharmaceutical formulation containing gelling agent

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.. .
Purdue Pharmaceuticals L.p.

Pharmaceutical solution formulations for pressurised metered dose inhalers

The invention relates to the prevention and/or treatment of a severe broncho-pulmonary disease by administering a solution formulation from a pressurized metered dose inhaler capable of providing therapeutical doses of two or more active drug substances to the lung, wherein all the active drug substances are fully dissolved in the formulation as well as the two or more active drug substances are delivered with substantially the same particle size distribution.. .
Chiesi Farmaceutici S.p.a.

Partially erodable systems for treatment of obstructive sleep apnea

The invention relates to devices and methods for reforming tissue surrounding the airway of a subject suffering from obstructive sleep apnea so as to open the airway and alleviate the occurrence of apneic events. Devices comprise a combination of resiliently deformable material and bioerodible material.

Therapeutically active compounds and their methods of use

Provided are methods of treating a cancer characterized by the presence of a mutant allele of idh1/2 comprising administering to a subject in need thereof a compound described here.. .
Agios Pharmaceuticals, Inc.

Hand therapy kit

A hand therapy kit includes a housing having a lid that is expandable from a folded position to an unfolded position to expose a working surface on an inside of the lid. An elastic cord is attached at two or more anchor points on the working surface to define at least one gap for receiving a finger.
Isos Solutions Llc

Multi-arm polymer prodrugs

Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule.
Nektar Therapeutics

Fkbp52-tau interaction as a novel therapeutical target for treating the neurological disorders involving tau dysfunction

The invention relates generally to neuroprotection and repair in neurological disorders involving tan dysfunction (including alzheimer's disease). The invention describes and includes a direct interaction between proteins fkbp52 mid tau.
Institut National De La Sante Et De La Recherche Medicale (inserm)

Method for treating cancer

A method for the treatment of cancer by administering a therapeutically effective amount of a cyclin-dependent kinase (cdk) inhibitor with a therapeutically effective amount of a b cell chronic lymphocytic leukemia/lymphoma 2 inhibitor (“b cell cll/lymphoma 2”, or “bcl-2”). Administration of the cdk inhibitor and bcl-2 inhibitor can be simultaneous, successive or separate..
Merck Sharp & Dohme Corp.

Booster drug therapy for mycobacterium infections

In one embodiment, the invention provides a method of treating a subject who suffers from, or who is suspected of suffering from, a mycobacterium infection, the method comprising administering to the subject a therapeutically effective amount of a urease inhibitor, optionally in combination with one or more anti-mycobacterial agents.. .
Stc.unm

Co-targeting androgen receptor splice variants and mtor signaling pathway for the treatment of castration-resistant prostate cancer

The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound of formula (i), and/or their subgenra, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein r1, r2, r3, r8, r9, r11a, r11b, r11c, and r11d are as defined herein, and at least one therapeutically active agents selected from inhibitors of pi3k/akt/mtor pathway, active agents associated with the treatment of prostate cancer, and anticancer agents.. .
British Columbia Cancer Agency Branch

Methods for treating cancer using nucleic acids targeting mdm2 or mycn

Aspects of the invention relate to methods for treating cancer by administering to a subject in need thereof a therapeutically effective amount of a nucleic acid molecule that is directed against a gene encoding mouse double minute 1 homolog (mdm1), mouse double minute 2 homolog (mdm2), mouse double minute 3 homolog (mdm3), mouse double minute 4 homolog (mdm4) or v-myc myelocytomatosis viral related oncogene (mycn) for treating cancer. Further aspects of the invention relate to nucleic acid molecules and compositions comprising nucleic acid molecules..
Rxi Pharmaceuticals Corporation

Method and composition for diagnosis or treatment of aggressive prostate cancer

Methods, pharmaceutical formulations and medicaments for treating prostate cancer or preventing the progression of a nonaggressive form of prostate cancer to an aggressive form, in a mammal, include a therapeutically effective amount of one or more active agents that reduce the expression or biological activity of both forkhead box protein m1 (foxm1) and centromere protein f (cenpf) or biologically active fragments thereof or biologically active fragments thereof selected from the group consisting of an isolated shrna, sirna, antisense rna, antisense dna, chimeric antisense dna/rna, microrna, and ribozymes that are sufficiently complementary to either a gene or an mrna encoding either foxm1 or cenpf proteins. A method is also presented for discovering synergistic master regulators of other phenotype transitions, wherein the master regulators are conserved among different species..
The Trustees Of Columbia University In The City Of New York

Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof

The present invention provides antibodies that bind to prostate-specific membrane antigen (psma), bispecific antibodies that bind to psma and cd3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human psma with high affinity and bind cd3 to induce human t cell proliferation.
Regeneron Pharmaceuticals, Inc.

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the nrp-1/obr signaling pathway..
Universite De Bourgogne

Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same

Wherein r is h, a methyl group, an ethyl group, a n-propyl group, an iso-propyl group, or a n-butyl group; and r1 is h, a 4′-methyl group, a 4′-oh, a 4′-ome group, a 2′,3′-c2h4 group, a; 3′,4′-c2h4 group, a 3′,4′-dif, a 3′,4′,5′-trif, or a 4′-ocf3; and optionally including a salt or a hydrate of said compound, and further provides a pharmaceutical composition comprising the compound of formula i and one or more acceptable pharmaceutical carriers. A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of formula i, or a pharmaceutical composition comprising a compound of formula i and one or more acceptable pharmaceutical carriers to the patient is disclosed..

Compounds and therapeutical use thereof

Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs..
Immune Pharmaceuticals, Inc.

Complexing agents for compositions containing inclusion complexes

The invention provides a composition containing particulate composite of a polymer and a therapeutic agent. The composition also contains a complexing agent.
Calando Pharmaceuticals, Inc.

Methods and pharmaceutical compositions for treating vaso-occlusive crisis

The present invention relates to methods and pharmaceutical compositions for treating vaso-occlusive crises. In particular, the present invention relates to a method of treating a vaso-occlusive crisis in a subject in need thereof comprising administering to the subject a therapeutically effective amount of agent capable of degrading, destabilizing or depleting the blood-borne extracellular dna from the blood of the subject..
Assistance Publique-hopitaux De Paris (aphp)

Method for medical treatment

The disclosure provides improved methods for treating or preventing a class of undesired health events including multiple related maladies, such as a disease, condition, or syndrome or the like. The improvement results from optimization of energy metabolism by administering a therapeutically effective compound selected to a) modulate mitochondrial activity to correct for deficiencies resulting from the disease, b) to boost cell energy metabolism thereby improving the original method's efficacy, and/or c) to correct for metabolic disruptions resulting from therapies or medicaments used in the method to be improved.

Strontium based compositions and formulations for pain, pruritus, and inflammation

Therapeutically-active compositions and formulations for treating pain, pruritus, irritation, inflammation, and tissue damage due to the irritation and inflammation, and therapeutically-active compositions and formulations for wound management, including wounds that are at high risk for infection. Strontium and beta hydroxybutyrate based compositions and formulations which can be topically applied..
Cosmederm Bioscience, Inc.

Methods and pharmaceutical compositions for the treatment of symptoms of anxiety and panic using beta adrenergic receptor antagonist and muscarinic receptor antagonist combinations

The present invention is focused primarily toward pro re nata (“as needed”) treatments for a psychiatric condition or disorder or the symptoms thereof, including the symptoms of acute anxiety and panic in living animals, including humans. The present invention encompasses pharmaceutical compositions as combination therapies containing at least one beta adrenergic receptor antagonist and at least one muscarinic receptor antagonist.
Thomas P. Dooley, Phd.

Histone deacetylase as a modulator of pdl1 expression and activity

Disclosed herein is a method for modulating program death receptor ligand 1 (pdl1) in a cancer cell, comprising contacting the cell with a composition comprising a histone deacetylase (hdac) inhibitor. Also disclosed is a method for treating a tumor in a subject, comprising administering to the subject a therapeutically effective amount of a composition comprising a histone deacetylase (hdac) inhibitor and a composition comprising a therapeutically effective amount of a program death receptor ligand 1 (pdl1) inhibitor, a programmed death 1 receptor (pd1) inhibitor, or a combination thereof..
H. Lee Moffitt Cancer Center And Research Institute, Inc.

Inhibitors for treating diseases characterized by atrial enlargement or remodeling

The present invention relates to the nep inhibitor pro-drug n-(3-carboxy-1-oxopropyl)-(4s)-p-phenylphenylmethyl)-4-amino-(2r)-methylbutanoic acid ethyl ester, or a pharmaceutically acceptable salt thereof; or the nep inhibitor n-(3-carboxy-1-oxopropyl)-(4s)-p-phenylphenylmethyl)-4-amino-(2r)-methylbutanoic acid, or a pharmaceutically acceptable salt thereof, pro-drug for use in the treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling; a method for treatment, prevention or delay of progression of a disease characterized by atrial enlargement and/or remodeling comprising administration of a therapeutically effective amount, or a prophylactically effective amount, of the nep inhibitor or the nep inhibitor pro-drug, or a pharmaceutically acceptable salt pro-drug thereof, to a subject, e.g. A human subject, in need of such treatment.
Novartis Ag

Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described..
Imprimis Pharmaceuticals, Inc.

Inositol-containing comestible units and methods of treatment using the same

A method for treating a patient having one or more of anxiety, hypersensitivity, restricted areas of interest, repetitive behaviors, irritability and emotional lability, or otherwise requiring a calming effect, is disclosed. The method includes administering to the patient a plurality of comestible units, e.g., cookies, cumulatively comprising a therapeutically effective amount of inositol..



Therapeutical topics:
  • Therapeutical
  • Carvedilol
  • Respiratory
  • Smoking Cessation
  • Respiratory Tract
  • Neurological
  • Proliferation
  • Immune System
  • Eating Disorder
  • Immune Response
  • Eating Disorders
  • Mosquito Bite
  • Plasmodium
  • Cardiovascular Health
  • Haematococcus Pluvialis


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Therapeutical for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Therapeutical with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.1719

    file did exist - 2692

    2 - 1 - 55